Developmental changes in pharmacokinetics and pharmacodynamics of warfarin enantiomers in Japanese children
- PMID: 11103757
- DOI: 10.1067/mcp.2000.110977
Developmental changes in pharmacokinetics and pharmacodynamics of warfarin enantiomers in Japanese children
Abstract
Objective: To clarify developmental changes in the pharmacokinetics and dynamics of warfarin enantiomers to establish rational pediatric dosage.
Methods: Plasma concentrations of unbound warfarin enantiomers, vitamin K1 and vitamin K-dependent proteins (that is, prothrombin fragments 1+2, protein C, and the protein-induced by vitamin K absence) and international normalized ratio were measured in 38 prepubertal (1 to 11 years), 15 pubertal (12 to 18 years), and 81 adult (37 to 76 years) patients given long-term warfarin therapy. Unbound oral clearance values for warfarin enantiomers and its body weight-, body surface area-, and liver weight-normalized values, as well as the pharmacodynamic parameters, were compared among the groups.
Results: The prepubertal, pubertal, and adult patients exhibited comparable mean plasma concentrations of unbound warfarin enantiomers for pharmacologically more active (S)-warfarin. Although the unbound oral clearance of (S)-warfarin for the prepubertal patients was significantly (P < .01) less than that for the adult group (346 versus 637 mL/min), the body weight-normalized unbound oral clearance for the prepubertal patients was significantly (P < .01) greater than that for the adults and showed a negative correlation (P < .05) with age. In contrast, no differences were observed in the liver weight-normalized unbound oral clearance for (S)-warfarin between the prepubertal and adult groups. The prepubertal patients showed significantly (P < .01 or .05) lower plasma concentrations of protein C and prothrombin fragments 1+2 and greater international normalized ratio and international normalized ratio/dose than the adults. In contrast, the pubertal patients showed largely similar pharmacokinetic and pharmacodynamic properties to adults.
Conclusion: Liver weight may be a better parameter than body weight for estimating the warfarin doses for prepubertal patients on the basis of the corresponding adult values. Augmented responses to warfarin in children should also be taken into account for estimating warfarin doses for children.
Similar articles
-
Potentiation of anticoagulant effect of warfarin caused by enantioselective metabolic inhibition by the uricosuric agent benzbromarone.Clin Pharmacol Ther. 1999 Dec;66(6):569-81. doi: 10.1053/cp.1999.v66.103378001. Clin Pharmacol Ther. 1999. PMID: 10613612
-
Interindividual variability in sensitivity to warfarin--Nature or nurture?Clin Pharmacol Ther. 2001 Aug;70(2):159-64. doi: 10.1067/mcp.2001.117444. Clin Pharmacol Ther. 2001. PMID: 11503010
-
Pharmacokinetic interaction between warfarin and a uricosuric agent, bucolome: application of In vitro approaches to predicting In vivo reduction of (S)-warfarin clearance.Drug Metab Dispos. 1999 Oct;27(10):1179-86. Drug Metab Dispos. 1999. PMID: 10497145
-
Pharmacogenetics of warfarin elimination and its clinical implications.Clin Pharmacokinet. 2001;40(8):587-603. doi: 10.2165/00003088-200140080-00003. Clin Pharmacokinet. 2001. PMID: 11523725 Review.
-
Warfarin and other coumarin derivatives: pharmacokinetics, pharmacodynamics, and drug interactions.Semin Vasc Med. 2003 Aug;3(3):221-30. doi: 10.1055/s-2003-44457. Semin Vasc Med. 2003. PMID: 15199454 Review.
Cited by
-
Pharmacogenomics in Children.Methods Mol Biol. 2022;2547:569-593. doi: 10.1007/978-1-0716-2573-6_20. Methods Mol Biol. 2022. PMID: 36068477
-
Evaluation of pharmacokinetics of warfarin from validated pharmacokinetic-pharmacodynamic model.ADMET DMPK. 2021 Jan 18;9(2):143-149. doi: 10.5599/admet.909. eCollection 2021. ADMET DMPK. 2021. PMID: 35299771 Free PMC article.
-
Optimal therapy for acute lymphoblastic leukemia in adolescents and young adults.Nat Rev Clin Oncol. 2011 May 31;8(7):417-24. doi: 10.1038/nrclinonc.2011.77. Nat Rev Clin Oncol. 2011. PMID: 21629213 Review.
-
Factors affecting serum phenobarbital concentration changes in pediatric patients receiving elixir and powder formulations.J Pharm Health Care Sci. 2021 Feb 2;7(1):7. doi: 10.1186/s40780-021-00190-2. J Pharm Health Care Sci. 2021. PMID: 33526089 Free PMC article.
-
How children's responses to drugs differ from adults.Br J Clin Pharmacol. 2005 Jun;59(6):670-3. doi: 10.1111/j.1365-2125.2005.02445.x. Br J Clin Pharmacol. 2005. PMID: 15948930 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical